Search

Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease

Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform

Outlook for Partnering in Animal Health 2024

Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.

2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic

Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer

The power of patient advocacy in cancer care

Patients and advocacy organizations agree that patient empowerment is key to quality cancer care

Building Successful Partnerships in Animal Health

Christoph Vetten, Head of Transactions Animal Health, shares his perspectives on how building successful collaborations can drive innovation.

Improving Access to Clinical Trials

Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials

Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies

FDA Grants Fast Track to Jardiance® (empagliflozin) for CKD | Boehringer Ingelheim US

The FDA has granted Fast Track designation for JARDIANCE to reduce risk of disease progression and CV death with CKD. View ISI, PI & Med Guide.

Jardiance® (empagliflozin) Granted Designation for Heart Failure | Boehringer Ingelheim US

The FDA granted Breakthrough Therapy designation for JARDIANCE® (empagliflozin) as treatment for HFpEF. View ISI, PI and Med Guide.

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fractio

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fraction

First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones

First half 2019: High levels of investment in R&D and robust organic growth

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

BI & Lilly Announce Outcome of FDA Advisory Meeting | Boehringer Ingelheim US

The EASE phase III program includes two Phase III clinical trials to investigate the efficacy, safety and tolerability of once-daily Empagliflozin.

Yankees Legend Bernie Williams Teams Up With Multi-Platinum Recording Artist and Actress Jordin Sparks to Unveil New Song Featuring Lyrics From The Breathless® Ballad Challenge Winner

Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer’s trials

Boehringer Ingelheim Acquires AMAL Therapeutics

FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors

Collaboration with Mary Tyler Moore Vision Initiative

Boehringer Ingelheim joins forces with Mary Tyler Moore Vision Initiative to combat vision loss from diabetes

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers